338452-92-9

Usage

Uses

4-amino-2-chloronicotinaldehyde is a useful research chemical.

InChI:InChI=1/C6H5ClN2O/c7-6-4(3-10)5(8)1-2-9-6/h1-3H,(H2,8,9)

Upstream product

• 893423-62-6 tert-butyl (2-chloro-3-formylpyridin-4-yl)carbamate 
• 234108-73-7 (2-chloro-pyridin-4-yl)-carbamic acid tert-butyl ester 
• 14432-12-3 4-Amino-2-chloropyridine 

Downstream Products

• 1032349-99-7 tert-butyl {1-[4-(5-chloro-3-phenyl-1,6-naphthyrindin-2-yl)phenyl]cyclobutyl}carbamate 
• 1032350-13-2 MK-2206 

Relevant academic research and scientific papers

HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS

The present invention provides heterocyclic compounds of formula (I), which are therapeutically useful as CBP/EP300 inhibitors. These compounds are useful in the treatment and/or prevention of diseases or disorders mediated by CBP and/or EP300 in an individual. The present invention also provides preparation of the compounds and pharmaceutical compositions comprising at least one of the compounds of formula (I) or a pharmaceutically acceptable salt, or a stereoisomer or a tautomer, an N-oxide or an ester thereof.

IL-23 ANTAGONISTS FOR TREATMENT OR PREVENTION OF SKIN RASH ASSOCIATED WITH TREATMENT WITH P13K/AKT PATHWAY INHIBITORS

The present invention provides methods for use of interleukin-23 (IL-23) antagonists to treat or prevent skin rash associated with treatment with PI3K/AKT pathway inhibitors, such as treatment of cancer.

Polyazanaphthalene compounds and pharmaceutical use thereof

The present invention relates to an inhibitor of matrix metalloprotease (MMP) production and tumor necrosis factor (TNF) production, and medicines for the treatment of diseases such as chronic rheumatoid arthritis, osteoarthritis, allergic diseases, psoriasis, transplant rejection, arterial sclerosis, ischemic re-perfusion disorder, diabetic nephritic and ocular diseases, cancer, autoimmune glomerulonephritis, infectious diseases, Crohn's disease, inflammatory intestinal diseases and autoimmune hepatitis, each comprising certain polyazanaphthalene compounds or pharmaceutically acceptable salts thereof as active ingredients.